Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia

Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia

Blog Article

Chimeric antigen receptor T-cell (CAR-T) therapy, which has demonstrated notable efficacy against B-cell malignancies and is approved by the US Food and Drug Administration for clinical use in this context, represents a significant milestone in cancer immunotherapy.However, the efficacy of CAR-T Shipping Crates therapy for the treatment of acute myeloid leukemia (AML) is poor.The challenges associated with the application of CAR-T therapy for the clinical treatment of AML include, but are not limited to, nonspecific distribution of AML therapeutic targets, difficulties in the production of CAR-T cells, AML blast cell heterogeneity, the immunosuppressive microenvironment in AML, Accessories and treatment-related adverse events.In this review, we summarize the recent findings regarding various therapeutic targets for AML (CD33, CD123, CLL1, CD7, etc.

) and the results of the latest clinical studies on these targets.Thereafter, we also discuss the challenges related to CAR-T therapy for AML and some promising strategies for overcoming these challenges, including novel approaches such as gene editing and advances in CAR design.